Vistagen announces results of successful u.s. phase 1 study of itruvone (ph10), enabling u.s. phase 2b development for treatment of major depressive disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced favorable safety and tolerability data from its u.s. phase 1 clinical trial of itruvone (ph10), the company's investigational rapid-onset pherine nasal spray for the treatment of major depressive disorder (mdd). results fro.
VTGN Ratings Summary
VTGN Quant Ranking